Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Cosenza

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Cancer Chemotherapy and Pharmacology|May 26, 2009
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agentAmy W Chun, Stephen C Cosenza, David R Taft, et al.
Molecular and Cellular Biology|January 5, 2002
Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescenceSushil G Rane, Stephen C Cosenza, Richard V Mettus, et al.
Oncotarget|April 9, 2019
Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasiaStacey J Baker, Stephen C Cosenza, M V Ramana Reddy, et al.
Nuclear Medicine and Biology|May 15, 2007
Differences in binding of (99m)Tc-disintegrins to integrin alphavbeta3 on tumor and vascular cellsLinda C Knight, Jan E Romano, Stephen C Cosenza, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2014
Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140Rafiqa Eachkoti, M V Ramana Reddy, Yen K Lieu, et al.
Plos One|March 19, 2013
ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathwayAnthony D Kang, Stephen C Cosenza, Marie Bonagura, et al.
Journal of Pharmaceutical and Biomedical Analysis|December 25, 2012
Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MSSool Yeon Cho, Stephen C Cosenza, Venkat Pallela, et al.
Bioorganic & Medicinal Chemistry|April 6, 2005
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1Natala Srinivasa Reddy, Kiranmai Gumireddy, Muralidhar R Mallireddigari, et al.
Organic & Biomolecular Chemistry|February 7, 2013
Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agentVenkat R Pallela, Muralidhar R Mallireddigari, Stephen C Cosenza, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2005
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistanceKiranmai Gumireddy, Stacey J Baker, Stephen C Cosenza, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Pharmacology|May 26, 2009
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agentAmy W Chun, Stephen C Cosenza, David R Taft, et al.
Molecular and Cellular Biology|January 5, 2002
Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescenceSushil G Rane, Stephen C Cosenza, Richard V Mettus, et al.
Oncotarget|April 9, 2019
Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasiaStacey J Baker, Stephen C Cosenza, M V Ramana Reddy, et al.
Nuclear Medicine and Biology|May 15, 2007
Differences in binding of (99m)Tc-disintegrins to integrin alphavbeta3 on tumor and vascular cellsLinda C Knight, Jan E Romano, Stephen C Cosenza, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2014
Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140Rafiqa Eachkoti, M V Ramana Reddy, Yen K Lieu, et al.
Plos One|March 19, 2013
ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathwayAnthony D Kang, Stephen C Cosenza, Marie Bonagura, et al.
Journal of Pharmaceutical and Biomedical Analysis|December 25, 2012
Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MSSool Yeon Cho, Stephen C Cosenza, Venkat Pallela, et al.
Bioorganic & Medicinal Chemistry|April 6, 2005
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1Natala Srinivasa Reddy, Kiranmai Gumireddy, Muralidhar R Mallireddigari, et al.
Organic & Biomolecular Chemistry|February 7, 2013
Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agentVenkat R Pallela, Muralidhar R Mallireddigari, Stephen C Cosenza, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2005
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistanceKiranmai Gumireddy, Stacey J Baker, Stephen C Cosenza, et al.
Pageof 3